Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
BioPharma DiveJonathan GardnerOctober 14, 2026
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.